|
Hep C Study Reveals Taribavirin a Good Alternative to Ribavirin
At the end of a 48-week, Phase IIb study, taribavirin shows similar effectiveness as ribavirin in reducing Hepatitis C viral load. However, participants taking taribavirin had a significantly lower rate of anemia....
Schering-Plough Developing Potent Protease Inhibitor for Hepatitis C
An ongoing Phase IIa study on Schering-Plough's next generation Hepatitis C protease inhibitor is encouraging. According to the company, SCH 900518 is 10 times more potent than other medications in this class and is active against highly resistant Hepatitis C...
New Drug Finds Viral Hiding Spots
A new, experimental drug helps the immune system locate a virus by flagging cells that have turned inside out. Hepatitis C is among the viruses that could benefit from Bavituximab's unique strategy of exposing a virus in hiding....
|
|
|
Safety and Immunogenicity of
Hepatitis A Vaccine in Patients With Chronic Liver Disease
|
table 1. Subject Characteristics
at Enrollment
|
|
|
Healthy (n = 188) |
Chronic Hepatitis C Vaccinated With Hepatitis A Vaccine (n = 104) |
Chronic Hepatitis C Vaccinated With Hepatitis B Vaccine (n = 67) |
Chronic Hepatitis B (n = 46) |
Other CLD (n = 70) |
|
| Mean age (range) (yr) |
39.8 (19-73) |
40.9 (23-69) |
45.0 (25-67) |
38.3 (18-67) |
43.1 (20-70) |
| Gender ratio (M/F)* |
47.8/52.2 |
63.8/35.2 |
68.7/31.3 |
71.7/28.3 |
53.6/46.4 |
| Serological status |
 seronegative for markers for hepatitis A, B and C |
anti-HCV positive |
anti-HCV positive |
HBsAg positive in two blood samples 6 months apart |
seronegative for markers for hepatitis A, B and C |
|
|
seronegative for markers for hepatitis A |
seronegative for markers for hepatitis B |
seronegative for markers for hepatitis A |
|
|
NOTE. ANOVA of mean ages was not significant for sex
(P = .91) and interaction sex-group (P = .67),
but was significant for group (P = .0015). Ratio
of males to females was significantly different (Fisher's Exact test,
P = .002).
Abbreviations: hepatitis A viral marker, anti-HAV; hepatitis C viral
marker, anti-HCV; hepatitis B viral marker, HBsAg, anti-HBs, anti-HBc,
anti-HDV, anti-HBe.
* Gender ratio expressed in percentage
(%).
Age and sex not recorded for one subject. |
|
Return To Article
|
|
